Tag: Erythropoiesis stimulating agents

Anemia affects an estimated 15.4% of adults with chronic kidney disease (CKD), with the prevalence rising to over 53% in stage 5 CKD [1.6.2]. For these patients, understanding **what to check before giving epoetin** is critical for safe and effective treatment.

The human kidneys produce erythropoietin, a vital hormone that regulates red blood cell production. But what is erythropoietin also known as? The most common short-hand for this hormone is EPO, a term widely used in both medical and athletic contexts.

EPOGEN (epoetin alfa), a medication used to treat anemia, carries a serious “Black Box Warning” from the FDA detailing increased risks of death, cardiovascular problems, and blood clots, especially when hemoglobin levels are pushed too high. This makes **Is EPOGEN a high risk medication?** a critical question for both patients and healthcare providers to address seriously before beginning treatment.

Procrit (epoetin alfa) is an erythropoiesis-stimulating agent (ESA) used to treat certain types of anemia caused by conditions like chronic kidney disease and chemotherapy. Over 20 million Americans are affected by chronic kidney disease, where Procrit and its alternatives are commonly utilized. Yes, there are several effective and often more affordable substitutes for Procrit, including biosimilars and other ESAs.

Anemia, a condition affecting millions, is often caused by a deficiency in red blood cells. When the body doesn't produce enough of these oxygen-carrying cells, certain medications are prescribed. So, what drug increases red blood cells and effectively treats anemia? The answer primarily involves a class of powerful agents known as erythropoiesis-stimulating agents (ESAs).